In the coronavirus-fueled bear market, Horizon Therapeutics (NASDAQ: HZNP) offers an attractive investment opportunity for healthcare investors. The specialty pharma delivered $1.3 billion in revenue in 2019 from a diverse portfolio of products. More importantly, it posted net income of $573 million or $2.90 per share. The stock has not outperformed the broader market year to date, but there are catalysts ahead that spell a likely change in direction for the company.
Here we'll explore what the future looks like, why investors should get excited for Horizon's prospects, and why buying in at today's price will ultimately be a bargain.
Image Source: Getty Images